Abstract
For more than a century, scientists have tried to exploit the anti-tumoral potential of the immune system to treat cancer. However, clinical success was traditionally limited. Consequently, classical anti-neoplastic treatments such as surgery, radiotherapy, and chemotherapy used to be the first line of treatment. Fortunately, this scenario is changing, particularly with the identification of immune checkpoint inhibitors. Now more than ever, it becomes essential to understand how cancer cells modulate the immune system. In this review, we summarize main mechanisms of antigen presentation in the tumor microenvironment, a main event in the establishment of anti-tumor immunity. Specifically, we focus on recent progress in mechanisms involved in tumor antigen presentation, as well as on strategies cancer cells develop to favor immune suppressive and immune tolerant enironments. In addition, we briefly discuss current therapeutic approaches to overcome tumor immune evasion.
Keywords: Antigen presenting cells, cancer, neoantigens, immunotherapy, immunosupression, immunotolerance.
Current Pharmaceutical Design
Title:Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Volume: 22 Issue: 41
Author(s): Daniela Cerezo-Wallis and Maria S. Soengas
Affiliation:
Keywords: Antigen presenting cells, cancer, neoantigens, immunotherapy, immunosupression, immunotolerance.
Abstract: For more than a century, scientists have tried to exploit the anti-tumoral potential of the immune system to treat cancer. However, clinical success was traditionally limited. Consequently, classical anti-neoplastic treatments such as surgery, radiotherapy, and chemotherapy used to be the first line of treatment. Fortunately, this scenario is changing, particularly with the identification of immune checkpoint inhibitors. Now more than ever, it becomes essential to understand how cancer cells modulate the immune system. In this review, we summarize main mechanisms of antigen presentation in the tumor microenvironment, a main event in the establishment of anti-tumor immunity. Specifically, we focus on recent progress in mechanisms involved in tumor antigen presentation, as well as on strategies cancer cells develop to favor immune suppressive and immune tolerant enironments. In addition, we briefly discuss current therapeutic approaches to overcome tumor immune evasion.
Export Options
About this article
Cite this article as:
Cerezo-Wallis Daniela and Soengas S. Maria, Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy, Current Pharmaceutical Design 2016; 22 (41) . https://dx.doi.org/10.2174/1381612822666160826111041
DOI https://dx.doi.org/10.2174/1381612822666160826111041 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Overexpression of miR-340-5p Inhibits Skin Fibroblast Proliferation by Targeting Kruppel-like Factor 2
Current Pharmaceutical Biotechnology Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery Personalized Peptide Vaccine for Treatment of Advanced Cancer
Current Medicinal Chemistry EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Impact of Epigenetic Dietary Components on Cancer through Histone Modifications
Current Medicinal Chemistry Recent Advances in Copper Radiopharmaceuticals
Current Radiopharmaceuticals Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?
Current Drug Targets Is Effective and Safe a Radiochemotherapy Approach in Elderly Cancer Patients? A Review
Anti-Cancer Agents in Medicinal Chemistry Is Type D Personality Here to Stay? Emerging Evidence Across Cardiovascular Disease Patient Groups
Current Cardiology Reviews Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Novel PARP Inhibitor DDPF-20 Induces DNA Damage and Inhibits Angiogenesis through the PI3K/Akt/VEGF Pathway
Anti-Cancer Agents in Medicinal Chemistry Role of Polysaccharides Mimetic Components in Targeted Cancer Treatment
Current Drug Targets The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging Advances in the Knowledge and Clinical Applications of Lactic Acid Bacteria as Probiotics in the Urogenital Tract
Current Women`s Health Reviews Plumbagin Inhibits Breast Tumor Bone Metastasis and Osteolysis by Modulating the Tumor-Bone Microenvironment
Current Molecular Medicine